InsiderTrades.com logo
Jason A. Keyes net worth and biography
  • LinkedIn

Jason Keyes Biography and Net Worth

Executive Vice President and Chief Financial Officer of BlossomHill Therapeutics

Jason Keyes, MBA, serves as the executive vice president and chief financial officer of BlossomHill Therapeutics. Prior to joining, Mr. Keyes served for over seven years as chief financial officer of Equillium, Inc. He has also served as chief financial officer of Orexigen Therapeutics, Inc. Over the course of his nearly 25-year career in the biotechnology industry, Mr. Keyes has also held various corporate finance and strategic planning roles at Amylin Pharmaceuticals, Inc., Amgen, Inc., and Baxter Healthcare Corporation. Mr. Keyes currently serves on the board of directors at Actuate Therapeutics, Inc., and previously served on the board of directors at Sesen Bio, Inc. Mr. Keyes received B.S. and M.S. degrees in civil engineering from Stanford University as well as an MBA from the Anderson School at UCLA.

What is Jason A. Keyes' net worth?

The estimated net worth of Jason A. Keyes is at least $11.28 thousand as of August 10th, 2026. Mr. Keyes owns 700 shares of BlossomHill Therapeutics stock worth more than $11,284 as of August 21st. This net worth evaluation does not reflect any other assets that Mr. Keyes may own. Learn More about Jason A. Keyes' net worth.

How do I contact Jason A. Keyes?

The corporate mailing address for Mr. Keyes and other BlossomHill Therapeutics executives is , ,. Learn More on Jason A. Keyes' contact information.

Has Jason A. Keyes been buying or selling shares of BlossomHill Therapeutics?

During the last ninety days, Jason A. Keyes has bought $11,200.00 in shares of BlossomHill Therapeutics stock. Most recently, on Monday, August 10th, Jason A. Keyes bought 700 shares of BlossomHill Therapeutics stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $11,200.00. Following the completion of the transaction, the chief financial officer now directly owns 700 shares of the company's stock, valued at $11,200. Learn More on Jason A. Keyes' trading history.

Who are BlossomHill Therapeutics' active insiders?

BlossomHill Therapeutics' insider roster includes Bihua Chen (Director), Carl Gordon (Director), and Jason Keyes (Executive Vice President and Chief Financial Officer). Learn More on BlossomHill Therapeutics' active insiders.

Are insiders buying or selling shares of BlossomHill Therapeutics?

In the last year, BlossomHill Therapeutics insiders bought shares 7 times. They purchased a total of 1,573,900 shares worth more than $25,181,900.00. The most recent insider tranaction occured on August, 10th when Director John P Schmid bought 6,000 shares worth more than $96,000.00. Learn More about insider trades at BlossomHill Therapeutics.

Information on this page was last updated on 8/10/2026.

Jason A. Keyes Insider Trading History at BlossomHill Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2026Buy700$16.00$11,200.00700View SEC Filing Icon  
See Full Table

Jason A. Keyes Buying and Selling Activity at BlossomHill Therapeutics

This chart shows Jason A Keyes's buying and selling at BlossomHill Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BlossomHill Therapeutics Company Overview

BlossomHill Therapeutics logo
BlossomHill Therapeutics Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $16.11
Low: $15.75
High: $16.50

50 Day Range

MA: N/A

2 Week Range

Now: $16.11
Low: $15.25
High: $17.25

Volume

39,232 shs

Average Volume

286,258 shs

Market Capitalization

$493.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A